XML 13 R2.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Current Assets    
Cash and cash equivalents $ 16,512 $ 14,032
Marketable securities 18,061 11,125
Prepaid and other current assets 758 815
Total current assets 35,331 25,972
Property and equipment, net 57 100
Other assets 614 1,081
Total assets 36,002 27,153
Liabilities    
Accounts payable 1,020 1,490
Accrued liabilities 2,486 4,486
Total current liabilities 3,506 5,976
Other long-term liabilities 254 624
Total liabilities 3,760 6,600
Commitments and Contingencies
Stockholders' Equity    
Preferred stock; authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 0.001 share of common stock, $0.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at December 31, 2020 and December 31, 2019, respectively 0 0
Common stock, $0.001 par value, authorized 500,000,000 shares; issued 19,389,413 and 10,528,689 shares, at December 31, 2020 and December 31, 2019, respectively; and outstanding, 19,378,333 and 10,517,609 shares, at December 31, 2020 and December 31, 2019, respectively 19 11
Additional paid-in capital 458,748 438,911
Treasury stock, at cost; 11,080 shares at December 31, 2020 and December 31, 2019 respectively (708) (708)
Accumulated deficit (425,550) (417,400)
Accumulated other comprehensive (loss) income (13) 2
Total Caladrius Biosciences, Inc. stockholders' equity 32,496 20,816
Noncontrolling interests (254) (263)
Total equity 32,242 20,553
Total liabilities, non-controlling interests and equity $ 36,002 $ 27,153